Evaluating the Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2025 Status changed from active, no longer recruiting to completed.
- 11 Dec 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 11 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.